MarketCap
Facebook
X
Telegram
InVivo Therapeutics Holdings Corp. Balance Sheet 2022-2007 | NVIV
Brief balance sheet overview of InVivo Therapeutics Holdings Corp.
The balance sheet is assessed across five available annual reports spanning 2018 to 2022.
Assets changed little, standing at $18.4 million initially and $18.8 million at the end. The balance sheet stayed close to its former scale.
Funding shifted toward liabilities: they gained +35.7%, compared with +2.4% for assets.
The equity-to-assets ratio is 83.7%, compared with 87.7% five periods ago. The balance sheet has a substantial internal cushion.
Negative net debt of -$15.4 million means cash holdings are larger than debt obligations.
Cash represents 86.9% of assets versus 90.7% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$248.6 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
InVivo Therapeutics Holdings Corp.'s financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet InVivo Therapeutics Holdings Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-15.4 M | -17.7 M | -18.5 M | -5.29 M | -16.6 M | -12.5 M | -20.6 M | -13.6 M | -11.9 M | -12 M | -11.2 M | -4.28 M | - | - | - | - |
Long Term Debt |
553 K | 949 K | 693 K | 1.02 M | - | 400 K | 852 K | 1.28 M | 1.6 M | 1.94 M | 1.58 M | 83.8 K | - | - | - | - |
Long Term Debt Current |
396 K | 361 K | 327 K | 294 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 752 K | 1.08 M | 61 K | 823 K | 987 K | 1.55 M | 1.6 M | 1.94 M | 1.58 M | 122 K | - | - | - | - |
Total Current Liabilities |
2.47 M | 2.61 M | 1.97 M | 2.66 M | 2.2 M | 3.11 M | 4.85 M | 3.31 M | 8.78 M | 2.27 M | 16.8 M | 36.7 M | 11.2 M | - | - | - |
Total Liabilities |
3.08 M | 3.66 M | 2.72 M | 3.74 M | 2.27 M | 3.94 M | 5.84 M | 4.86 M | 10.8 M | 4.21 M | 18.4 M | 36.9 M | 11.2 M | - | - | - |
Retained Earnings |
-249 M | -238 M | -228 M | -219 M | -207 M | -184 M | -157 M | -134 M | -100 M | -81.9 M | -43.2 M | -47.8 M | - | - | - | - |
Total Assets |
18.8 M | 21.8 M | 21.9 M | 9.32 M | 18.4 M | 14 M | 34.8 M | 21.8 M | 16.7 M | 17.1 M | 16.1 M | 5.7 M | 9.38 M | - | - | - |
Cash and Cash Equivalents |
16.4 M | 19 M | 19.5 M | 6.6 M | 16.7 M | 12.9 M | 21.5 M | 14.9 M | 13.5 M | 14 M | 12.8 M | 4.36 M | 8.96 M | 227 K | - | - |
Book Value |
15.7 M | 18.1 M | 19.2 M | 5.58 M | 16.1 M | 10.1 M | 28.9 M | 16.9 M | 5.92 M | 12.9 M | -2.31 M | -31.2 M | -1.85 M | - | - | - |
Total Shareholders Equity |
15.7 M | 18.1 M | 19.2 M | 5.58 M | 16.1 M | 10.1 M | 28.9 M | 16.9 M | 5.92 M | 12.9 M | -2.31 M | -31.2 M | -1.85 M | -3.62 M | -2.62 M | -1.08 M |
All numbers in USD currency
Quarterly Balance Sheet InVivo Therapeutics Holdings Corp.
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
553 K | 280 K | 417 K | 553 K | 656 K | 755 K | 853 K | 949 K | 530 K | 629 K | 605 K | 693 K | 779 K | 861 K | 944 K | 1.02 M | 1.1 M | 1.17 M | 1.28 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
666 K | 1.76 M | 2.18 M | 3.08 M | 3.26 M | 3.26 M | 3.02 M | 3.66 M | 2.63 M | 2.5 M | 2.16 M | 2.72 M | 2.7 M | 2.71 M | 2.87 M | 3.74 M | 3.29 M | 3.14 M | 3.43 M | 2.27 M | 2.99 M | 25.8 M | 4.97 M | 3.94 M | 4.34 M | 4.61 M | 4.98 M | 5.84 M | 6.64 M | 5.9 M | 6.2 M | 4.86 M | 6.92 M | 11.9 M | 16.7 M | 10.8 M | 6.74 M | 9.7 M | 3.93 M | 4.21 M | 4.05 M | 3.48 M | 28.2 M | 18.4 M | 13 M | 24.7 M | 29.9 M | 36.9 M | 5.19 M | 9.89 M | 36.9 M |
Retained Earnings |
-256 M | -253 M | -251 M | -249 M | -246 M | -244 M | -241 M | -238 M | -235 M | -233 M | -230 M | -228 M | -226 M | -224 M | -222 M | -219 M | -216 M | -213 M | -210 M | -207 M | -205 M | -202 M | -189 M | -184 M | -179 M | -170 M | -164 M | -157 M | -152 M | -145 M | -140 M | -134 M | -129 M | -127 M | -116 M | -100 M | -100 M | -100 M | -100 M | -81.9 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
9.58 M | 13.3 M | 15.7 M | 18.8 M | 13.4 M | 16.1 M | 18.5 M | 21.8 M | 23.6 M | 25.8 M | 27.7 M | 21.9 M | 10.5 M | 12.7 M | 12.4 M | 9.32 M | 11.1 M | 13.6 M | 17 M | 18.4 M | 21.5 M | 23.9 M | 13.3 M | 14 M | 18.6 M | 23.6 M | 29 M | 34.8 M | 39.5 M | 43.5 M | 47.7 M | 21.8 M | 24 M | 27.3 M | 27 M | 16.7 M | 20.3 M | 23.7 M | 13 M | 17.1 M | 21.6 M | 25.8 M | 13.8 M | 16.1 M | 18.5 M | 20 M | 21.4 M | 5.7 M | 4.6 M | 5.97 M | 5.7 M |
Cash and Cash Equivalents |
8.58 M | 10.7 M | 13.1 M | 16.4 M | 10.6 M | 13 M | 15.2 M | 19 M | 21.1 M | 23 M | 24.8 M | 19.6 M | 7.9 M | 9.82 M | 9.2 M | 6.6 M | 8.14 M | 9.9 M | 13.2 M | 16.7 M | 19.7 M | 22.3 M | 11.6 M | 12.9 M | 16.4 M | 14.3 M | 14.4 M | 21.5 M | 37.7 M | 41.6 M | 45.8 M | 14.9 M | 22.1 M | 25.1 M | 24.5 M | 13.5 M | 17.6 M | 20.8 M | 9.85 M | 14 M | 18.3 M | 22.2 M | 10.3 M | 12.8 M | 15.5 M | 18 M | 19.6 M | 4.36 M | 3.69 M | 4.96 M | 4.36 M |
Book Value |
8.92 M | 11.6 M | 13.5 M | 15.7 M | 10.1 M | 12.8 M | 15.5 M | 18.1 M | 20.9 M | 23.3 M | 25.5 M | 19.2 M | 7.81 M | 10 M | 9.56 M | 5.58 M | 7.86 M | 10.5 M | 13.5 M | 16.1 M | 18.5 M | -1.91 M | 8.32 M | 10.1 M | 14.3 M | 19 M | 24 M | 28.9 M | 32.8 M | 37.6 M | 41.5 M | 16.9 M | 17.1 M | 15.3 M | 10.3 M | 5.92 M | 13.6 M | 14 M | 9.06 M | 12.9 M | 17.6 M | 22.3 M | -14.3 M | -2.31 M | 5.49 M | -4.73 M | -8.46 M | -31.2 M | -590 K | -3.92 M | -31.2 M |
Total Shareholders Equity |
8.92 M | 11.6 M | 13.5 M | 15.7 M | 10.1 M | 12.8 M | 15.5 M | 18.1 M | 20.9 M | 23.3 M | 25.5 M | 19.2 M | 7.81 M | 10 M | 9.56 M | 5.58 M | 7.86 M | 10.5 M | 13.5 M | 16.1 M | 18.5 M | -1.91 M | 8.32 M | 10.1 M | 14.3 M | 19 M | 24 M | 28.9 M | 32.8 M | 37.6 M | 41.5 M | 16.9 M | 17.1 M | 15.3 M | 10.3 M | 5.92 M | 13.6 M | 14 M | 9.06 M | 12.9 M | 17.6 M | 22.3 M | -14.3 M | -2.31 M | 5.49 M | -4.73 M | -8.46 M | -31.2 M | -590 K | -3.92 M | -31.2 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of InVivo Therapeutics Holdings Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
